Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Investors should not bank on Medicare covering the powerful new weight-loss drugs from Eli Lilly & Co. LLY, -1.25%, Novo Nordisk NVO, +0.52% and other drugmakers any time soon, Beacon Policy Advisors said in a report Thursday. A decades-old law generally prohibits Medicare from covering prescription drugs for weight loss.

Medicare coverage of weight-loss drugs? Don't count on it, analysts say.

Sigilon Therapeutics

Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.

Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments

Eli Lilly & Co. LLY, -1.25% said Thursday it has agreed to acquire Sigilon Therapeutics in a deal worth up to $309.6 million, sending Sigilon's stock up more than 470% premarket. Under the terms of the deal, Lilly will pay $14.92 per Sigilon share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest.

Sigilon Therapeutics' stock soars 472% after Eli Lilly agrees to acquire company

INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.

Lilly to Acquire Sigilon Therapeutics

GlaxoSmithKline

Artificial intelligence is being used by the world's top drugmakers to speed up innovation in areas of high unmet medical need. GSK and Eli Lilly are both pioneers in the use of AI for drug discovery and development.

Better Artificial Intelligence Stock: GSK or Eli Lilly?

Eli Lilly's orforglipron appears to be the top contender in the weight loss pill space due to its strong efficacy data and ease of use.

As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge

Pfizer

Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long-term impact.

Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know.

Eli Lilly shares rose in early trading on Tuesday after a trial showed its retatrutide weight loss drug could help patients lose more weight than other drugs, including Novo Nordisk's Ozempic.

Eli Lilly Shares Rise After Drug Helps Patients Lose More Weight Than Competitors

Eli Lilly may have a best-in-class obesity care asset. In a mid-stage study, the drugmaker's weight loss drug produced a mean weight reduction of 24.2% at 48 weeks.

Why Eli Lilly Stock Briefly Popped Today

Eli Lilly And Co (NYSE:LLY) released mid-stage trial data earlier today showing its obesity drug candidate promoted weight loss of up to 24.2% after 48 weeks, beating competitors' results.

Eli Lilly Stock Nabs Record on Obesity Drug Trial Data

Altimmune

Amgen

Viking Therapeutics

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

Factbox: Weight-loss drugs: the next gold rush

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Eli Lilly Sets New Bar In Weight Loss And Nears Record High; Novo Nordisk Slips

Shares of Eli Lilly & Co. LLY, -1.33% gained 1.6% premarket on Tuesday after the company released new data late Monday on its investigational obesity drug retatrutide. The treatment resulted in average weight loss of up to 17.5%, or 41.2 pounds, after 24 weeks in patients with obesity or overweight and without diabetes, and average weight loss of up to 24.2%, or 57.8 pounds, after 48 weeks, according to results presented at the American Diabetes Association's scientific conference.

Eli Lilly shares gain after investigational obesity treatment helps patients lose up to 58 pounds, on average

UK's drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly's weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health Service (NHS).

More evidence needed on Lilly's weight loss drug, UK watchdog says

A new drug to tackle obesity cut the weight of participants by an average of 58 pounds at the end of its latest clinical trial, US drug giant Eli Lilly announced last night. Results from the trial of the new injectable drug retatrutide were released in the New England Journal of Medicine (NEJM) and The Lancet on Monday with clinicians said to be stunned by the weight loss achieved.

Eli Lilly stuns doctors as obesity drug sparks 24% weight loss

By 48 weeks, patients who took Eli Lilly's retatrutide lost 58 pounds on average, the pharmaceutical company said in a mid-stage clinical trial.

Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says

In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program INDIANAPOLIS , June 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweighti without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb.

Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight

Eli Lilly's mid-stage trial of its next-generation "triple g" obesity drug candidate found that the highest dose of the weekly injection to led to weight loss of 24.2% after 48 weeks, the New England Journal of Medicine said on its website on Monday.

Lilly experimental 'triple g' obesity drug leads to 24.2% weight loss in trial -NEJM

Akero Therapeutics Inc

89bio Inc

Madrigal Pharmaceuticals

Vertex Pharmaceuticals

Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.

Weight-loss drugs in development aim to replace injections with pills

INDIANAPOLIS , June 26, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Sept.

Lilly Declares Third-Quarter 2023 Dividend

Detailed results presented at the American Diabetes Association's® 83rd Scientific Sessions  Lilly has completed tirzepatide's submission for chronic weight management to the FDA INDIANAPOLIS , June 24, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in participants with obesity or overweighti and type 2 diabetes, showed that tirzepatide led to superior weight reduction versus placebo for both doses. The data were presented during a symposium at the American Diabetes Association's® (ADA) 83rd Scientific Sessions and were simultaneously published in The Lancet.

Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes

In additional phase 2 data, published in The Lancet, orforglipron achieved mean reduction in A1C up to 2.1% at 26 weeks in adults with type 2 diabetes Lilly is investigating orforglipron, its first nonpeptide oral GLP-1 receptor agonist, for chronic weight management in the ATTAIN phase 3 clinical program and for type 2 diabetes in the ACHIEVE phase 3 clinical program INDIANAPOLIS , June 23, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweighti. The results were shared during an oral presentation at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in the New England Journal of Medicine.

Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight

Results from a mid-stage trial found that the highest dose of Eli Lilly's experimental pill orforglipron helped people who were obese or overweight lose 14.7% of their body weight after 36 weeks, the company said on Friday.

Experimental Lilly pill leads to 14.7% weight loss in mid-stage trial

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.

News for Eli Lilly Stock (LLY)